The Coca-Cola Company (NYSE: KO) is one of the world’s largest beverage businesses, selling sparkling soft drinks, waters and sports drinks, juices and dairy, coffee, and ready-to-drink products through a global network of licensed bottling partners. It remains independently traded, and in December 2025 announced a CEO succession plan: longtime COO Henrique Braun succeeds James Quincey as CEO from 31 March 2026.
Coca-Cola has also navigated a politically charged 2025 decision to introduce a US cane-sugar version of Coca-Cola, following public pressure from the Trump administration‘s “Make America Healthy Again” campaign, while managing continued premiumisation through brands like Fairlife and BodyArmor.
Strengths
A distribution system rivals can’t easily match
A global network of licensed independent bottling partners lets Coca-Cola reach markets and shelf space at a cost most rivals cannot replicate.
A diversified beverage portfolio
Fairlife (protein/dairy), BodyArmor (sports drinks) and Costa Coffee reduce reliance on sugary carbonated drinks alone.
A genuine zero-sugar growth driver
Reformulated, “better-for-you” products have become a real growth line even amid broader industry pressure from GLP-1 weight-loss drugs.
Weaknesses
Structural pressure on core soda demand
Rising GLP-1 weight-loss drug adoption is projected by industry analysts to meaningfully dent calorie consumption from sugary drinks by the end of the decade.
Product decisions shaped by politics
The 2025 US cane-sugar variant, launched under political pressure, added cost and complexity without clear evidence of a meaningful sales benefit.
Ongoing plastic-waste scrutiny
Coca-Cola remains a frequent target of environmental campaigners over single-use bottle waste, an ongoing reputational and regulatory exposure.
Opportunities
Emerging-market growth
India, Africa and other high-population markets still have significant room to grow per-capita consumption compared with mature Western markets.
Functional and better-for-you categories
Further building protein drinks, hydration brands and zero-sugar sparkling drinks can capture health-conscious consumers shifting away from full-sugar soda.
A leadership reset
The CEO transition to Henrique Braun is a chance to sharpen portfolio focus and potentially accelerate decisions a long-tenured predecessor moved on more cautiously.
Threats
GLP-1 drugs as a long-term demand threat
If adoption continues to scale as projected, this represents a genuine structural threat to full-sugar carbonated beverages.
Politicised regulation of ingredients
Government and public-health pressure on sugar content and food dyes shows product formulation is now subject to politics, not just consumer taste.
Fast-growing “functional soda” challengers
Independent brands like Olipop and Poppi are eroding Coca-Cola’s share of the growing health-conscious beverage segment.
Applying the analysis
Illustrative recommendation: lead marketing for the zero-sugar and functional-beverage lines with the same distribution and brand-building playbook used for core Coca-Cola, rather than treating them as a side project.
Discuss and apply
1. Explain why GLP-1 weight-loss drugs count as a marketing threat rather than only a health trend.
2. Suggest one way Coca-Cola could respond to smaller “functional soda” challengers without discounting its core brand.
Suggested answer guidance
GLP-1 drugs reduce appetite and calorie intake at scale, directly shrinking the addressable market for sugary drinks — a demand-side threat, not just a health headline. A credible response might be acquiring or partnering with functional-soda brands, or accelerating Coca-Cola’s own zero-sugar innovation, rather than competing on price.
Compare this case with our McDonald’s SWOT analysis. Sources are linked beside the relevant evidence; recommendations and discussion activities are Marketing Teacher’s educational analysis.
